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ABSTRACT 
BACKGROUND: Mitochondria are the powerhouse of mammalian cells and the 
main source of reactive oxygen species (ROS) associated with oxygen 
consumption. In addition, they also play a strategic role in controlling the fate of 
cells through regulation of death pathways. Mitochondrial ROS production fulfills 
a signaling role through regulation of redox pathways, but also contributes to 
mitochondrial damage in a number of pathological states. SCOPE OF REVIEW: 
Mitochondria are exposed to the constant generation of oxidant species, and 
yet the organelle remains functional due to the existence of an armamentarium 
of antioxidant defense systems aimed to repair oxidative damage, of which 
mitochondrial glutathione (mGSH) is of particular relevance. Thus, the aim of 
the review is to cover the regulation of mGSH and its role in disease. MAJOR 
CONCLUSIONS: Cumulating evidence over recent years has demonstrated the 
essential role for mGSH in mitochondrial physiology and disease. Despite its 
high concentration in the mitochondrial matrix, mitochondria lack the enzymes 
to synthesize GSH de novo, so that mGSH originates from cytosolic GSH via 
transport through specific mitochondrial carriers, which exhibit sensitivity to 
membrane dynamics. Depletion of mGSH sensitizes cells to stimuli leading to 
oxidative stress such as TNF, hypoxia or amyloid β-peptide, thereby 
contributing to disease pathogenesis. GENERAL SIGNIFICANCE: 
Understanding the regulation of mGSH may provide novel insights to disease 
pathogenesis and toxicity and the opportunity to design therapeutic targets of 
intervention in cell death susceptibility and disease.  
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INTRODUCTION 
Despite its exclusive synthesis in the cytosol, GSH is distributed in intracellular 
organelles, including endoplasmic reticulum (ER), nucleus and mitochondria. 
The compartmentalization of GSH in separate redox pools is critical to control 
compartment-specific needs and functions [1, 2]. In the nucleus, GSH maintains 
critical protein sulphydryls that are necessary for DNA repair and expression [3] 
and functions also as a hydrogen donor in ribonucleotide reductase-catalysed 
reduction of ribonucleotides to deoxyribonucleotides, thus playing a contributory 
role in DNA synthesis[4]. Intracellularly GSH is predominantly found in its 
reduced form except in the ER, where it exists mainly as oxidized glutathione 
(GSSG), GSSG being the main source of oxidizing equivalents to provide the 
adequate environment necessary for disulphide bond formation and proper 
folding of nascent proteins [5]. In mitochondria, however, GSH is mainly found 
in reduced form and represents a minor fraction of the total GSH pool (10–
15%). Considering the volume of the mitochondrial matrix, the concentration of 
mitochondrial GSH (mGSH) is similar to that of cytosol (10–14 mM) [1, 2, 6, 7]. 
Mitochondria are an excellent example of subcellular organelles whose function 
is closely linked to maintenance of redox balance. The mitochondria are the 
primary intracellular site of oxygen consumption and the major source of 
reactive oxygen species (ROS), most of them originating from the mitochondrial 
respiratory chain. Associated with this constant flow of ROS generation 
mitochondria are a target for the damaging effects of oxygen radicals [8-10]. 
Although normal electron transport in mitochondria involves four-electron 
reduction of molecular oxygen to water, partial reduction reactions occur even 
under physiological conditions, causing release of superoxide anion (O·2-) and 
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hydrogen peroxide. In accordance with this, it has been estimated that the 
steady-state concentration of O·2- in the mitochondrial matrix is five- to tenfold 
higher than in the cytosol [11].  
In addition to the ROS generated under physiological settings, toxic or 
pathological conditions that lead to an impairment of mitochondrial function can 
increase the release of ROS. Therefore, although mitochondria are exposed to 
the constant generation of oxidant species, the organelle remains functional due 
to the existence of an antioxidant defense system, of which mGSH is a critical 
component, aimed to prevent or repair oxidative damage generated during 
normal aerobic metabolism. This review summarizes current knowledge on the 
physiology and function of mGSH and its role in cell death regulation and 
pathological states. 
 
1. Mitochondrial Oxidative Stress and defense 
The primary function of mitochondria is to transduce oxygen consumption in the 
electron transport chain (ETC) into energy required for myriad cell functions. 
Although the process is highly efficient, a small fraction of electrons are 
transferred directly to molecular oxygen, resulting in the generation of O2·-, 
which can give rise to other potent ROS as well as reactive nitrogen species 
(RNS). Therefore, a fine equilibrium between ROS production and removal will 
determine the physiological vs. pathological function of ROS. Mitochondria 
contain an arsenal of antioxidant systems with target specificity [1].  
Superoxide dismutase 
The first line of defense against ROS is guaranteed by the presence of Mn2+-
SOD (SOD2) in the mitochondrial matrix, which results in superoxide anion 
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dismutation and the subsequent generation of hydrogen peroxide. The 
relevance of this strategy is illustrated by the fact that global SOD2 deficiency 
leads to neonatal death in mice. In turn, control of hydrogen peroxide is 
achieved by the GSH redox system and other defenses such as glutaredoxins 
and thioredoxins, as depicted in Figure 1. Hydrogen peroxide can arise through 
sources other than via superoxide anion dismutation by SOD-2. For instance, 
p66Shc is a cytoplasmic protein involved in signaling from tyrosine kinases to 
Ras, which translocates to mitochondria in response to stress contributing to 
cell death and aging. It has been shown that p66Shc directly stimulates hydrogen 
peroxide generation, without inhibiting mitochondrial respiration, by transferring 
electrons to cytochrome c [12].  
Glutathione Redox Cycle 
Although hydrogen peroxide is not a free radical, it is an oxidant and an 
intermediate in the chain of reactions that generate reactive free radicals, such 
as hydroxyl radical, which can oxidize mitochondrial components (proteins, 
lipids, DNA). Since most mitochondria lack catalase, perhaps with the 
demonstrated exception of rat heart mitochondria [13], the metabolism of 
hydrogen peroxide is mainly accomplished by GSH, with the participation of 
either GSH peroxidase or peroxiredoxins. Associated with this function GSH 
becomes oxidized to GSSG, which is reduced back to GSH by the NADPH-
dependent GSSG reductase (GR), as shown in Figure 1. Among GSH 
peroxidases (Gpx) that detoxify hydrogen peroxide, Gpx1 is the major isoform 
localized mainly in the cytosol, with a small fraction also present in the 
mitochondrial matrix [2, 14]. Some potent electrophiles, especially those 
generated as a consequence of metabolic processes involving both 
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endogenous compounds and xenobiotics, can be readily removed by GSH via 
catalysis by glutathione transferases (GSTs). GSTs are distributed in 
mitochondria (GSTA1), cytosol (alpha, mu, pi, and zeta) and membrane-bound 
(MGST1) isoforms [15, 16]. Mitochondrial GSTs display both glutathione 
transferase and peroxidase activities that detoxify harmful byproducts through 
GSH conjugation or GSH-mediated peroxide reduction [15, 17].  Among human 
mitochondrial GSTs, the isoforms hGSTA4-4, hGSTA1, hGSTA2, and hGSTP1 
showed peroxidase activity, with hGSTA4-4 exhibiting the highest activity [18, 
19]. 
mGSH is also the primary defense against oxidative damage to mitochondrial 
membranes by insuring the reduction of hydroperoxides present on 
phospholipids and other lipid peroxides. These modified lipids are detoxified by 
mGSH through the actions of mitochondrial GSTs with modest Se-independent 
Gpx activity, as well as specific GSH peroxidases, such as Gpx4 which displays 
high preference for lipid hydroperoxides (Figure 1). Actually, due to its capacity 
to reduce hydroperoxide groups on phospholipids, cholesteryl esters and 
lipoproteins, Gpx4 is considered a critical defense enzyme in protecting 
membranes against oxidative stress. Gpx4 is synthesized in three forms that 
arise from the same Gpx4 gene displaying different translation initiation sites. A 
short form of Gpx4 is present in somatic tissue mitochondria and is essential for 
survival and protection against apoptosis in mice, whereas a long form has 
been shown to be important for male fertility [20-22]. Experiments using cell 
lines overexpressing Gpx4 have shown its critical role in reducing oxidative 
stress-mediated toxicity [23]. Interestingly, recent reports also suggest that 
Gpx4 plays a role in the protection against apoptosis and in maintenance of 
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oxidative phosphorylation complexes in gut epithelial cells [24], by a mechanism 
involving the protein Apoptosis Inducing Factor (AIF). In line with this, TNFα 
induced ROS formation, phospholipid peroxidation, mitochondrial damage, and 
apoptotic death in Jurkat cells, was prevented upon ectopic GPx4 expression 
[25]. Conversely, GPx4 siRNA knockdown enhanced phospholipid peroxidation, 
increasing TNFα-dependent apoptosis[25]. Moreover, due to its inner 
membrane location in mitochondria and its ability to repair cardiolipin 
peroxidation, Gpx4 differentially regulates apoptogenic protein from 
mitochondria [20]. The importance of Gpx4 is highlighted by the fact that while 
Gpx1 knockout mice are phenotypically normal and exhibit an expected 
lifespan, Gpx4 knockout mice die during early embryonic development [26] and 
Gpx4+/- cell lines are markedly sensitive to inducers of oxidative stress, 
including gamma-irradiation, tert-butyl-hydroperoxide, and hydrogen peroxide, 
as compared to cell lines derived from wild-type control littermates [14]. 
Additionally, Gpx4 has also been suggested to play an important role in life 
expectancy in mice [26, 27]. 
For both regulatory and antioxidant roles, it is important for protein thiol redox 
states to respond rapidly to changes in the GSH/GSSG ratio. Thiol-disulfide 
exchange between GSSG and a protein thiol or between a glutathionylated 
protein and GSH is often relatively slow [28]. A potential catalyst for thiol-
disulfide exchange is the small, soluble protein glutaredoxin (Grx) [28, 29]. Grx 
catalyzes the deglutathionylation of protein-glutathione mixed disulfides far 
more effectively than thioredoxin (Trx) or protein-disulfide isomerase [30]. Two 
known Grx isoforms are found in mammals, Grx1 and Grx2. Grx1 is of cytosolic 
expression, and Grx2 localizes to both the mitochondrial matrix and nucleus 
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[31]. The mitochondrial isoform Grx2, discovered in early 2000, is a mature 
protein of about 15 kDa [29, 31, 32] and displays an interesting characteristic of 
being reactivated directly by thioredoxin reductase (TrxR) as well as by GSH 
[33, 34] and is able to fully operate in more oxidatively stressed mitochondrial 
environment. Therefore, Grx2 is a candidate for catalyzing the interplay of the 
mitochondrial GSH pool with protein thiols during both antioxidant defense and 
redox signaling [29]. 
Thioredoxins 
Regarding the thioredoxin (Trx) system in mammals, both Trx and TrxR are 
expressed as isoforms for both predominantly cytosolic (Trx1 and TrxR1) or 
mitochondrial (Trx2 and TrxR2) localization [34]. There are direct links between 
the Trx system and protein glutathionylation [35]; and the direct reduction of 
mitochondrial Grx2 by TrxR is also of important physiological relevance [33, 34]. 
However, the reduction of the intermolecular disulfide is specific to Trx and can 
not be achieved by GSH or glutaredoxin. Mitochondria-specific Trx and TrxR, 
can interact also with the peroxiredoxins (Prxs), which constitute a novel family 
of thiol-specific peroxidases that rely on Trx as the hydrogen donor for the 
reduction of hydrogen peroxides and lipid-hydroperoxides [36].  
Peroxiredoxins 
One Prx isoform, Prx3, is exclusively detected in mitochondria, suggesting that 
Prx3 together with Trx2 and TrxR2 provide a primary line of defense against 
H2O2 produced by the mitochondrial respiratory chain.  Prx3 homodimer has a 
redox-sensitive cysteine that upon reaction with hydrogen peroxide is oxidized 
to Cys-SOH, which then reacts with neighboring Cys-SH of the other subunit to 
form an intermolecular disulfide that can be readily reduced by Trx2, but not by 
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Grx or GSH [10, 37]. The fact that the oxidation state of the active site cysteine 
of Prx can be transferred to other proteins that are less intrinsically susceptible 
to H2O2 also allows Prx to function as an H2O2 sensor. Similarly, Prx5 the last 
identified member of the six mammalian peroxiredoxins [38] is widely expressed 
in tissues but differs by its subcellular distribution. In human cells, it has been 
shown that Prx5 can be targeted to mitochondria, peroxisomes, the cytosol, and 
the nucleus. The targeting of Prx5 to mitochondria is highly conserved among 
species [39], and it has been associated with the protection of mtDNA from 
oxidative attacks [40]. Prx5 is a peroxidase that can use cytosolic or 
mitochondrial thioredoxins to reduce alkyl hydroperoxides or peroxynitrite with 
high rate constants, whereas its reaction with hydrogen peroxide is modest [38]. 
So far, Prx5 has been viewed mainly as a cytoprotective antioxidant enzyme 
rather than as a redox sensor. Thus, more than 10 years after its molecular 
cloning, mammalian Prx5 appears to be a unique peroxiredoxin exhibiting 
specific functional and structural features [38, 41].  
An interesting issue centers on the relative importance of the mitochondrial 
GSH redox  (mGSH/Gpx) vs PrxIII/Trx2 system on hydrogen peroxide defense. 
The relevance of GSH peroxidases, in particular the mitochondrial targeted 
Gpx4, in oxidative stress defense and hydrogen peroxide elimination is 
illustrated by the fact that Gpx4 knockout mice is embryonic lethal [26]. 
However, recent studies identified PrxIII as an essential line of defense against 
mitochondrial hydrogen peroxide [37], with the estimation by kinetic competition 
analysis that a large amount of hydrogen peroxide generated in mitochondria 
targets PrxIII [42].  In addition, selective depletion of mGSH has been shown to 
sensitize hepatocytes to oxidant cell death [2, 6, 8]. While differences in Km for 
Mari et al,  BBAGEN-12-0409-R 
 10
hydrogen peroxide, catalytic efficiency and Kcat may account for the relative 
importance of mGSH/Gpx and PrxIII/Trx2 against hydrogen peroxide, 
differences in abundance and post-translational regulation of these antioxidant 
components in different type of cells may also play a role. For instance, studies 
addressing the role of PrxIII in oxidative stress defense have been performed in 
HeLa cells [37], while reporting the role of mGSH in oxidant cell death have 
been typically done in primary hepatocytes [2, 6, 8]. Although further specific 
work addressing these features is needed, current evidence has shown that 
both antioxidant systems (mGSH and PrxIII) are clearly interconnected. For 
instance, it has been described that depletion of mGSH results in Trx2 oxidation 
[43]. Similarly, in a recent study using hypercholesterolemic pigs they observed 
a selective depletion of mGSH in heart mitochondria, with the spare of cytosol 
GSH that was followed by profound decreases in the levels of the mitochondria-
specific antioxidant enzymes such as MnSOD, Trx2, and PrxIII [44]. However, 
the influence of PrxIII on the GSH redox cycle status has not been addressed. 
Together, these data provide evidence for an essential role of the mitochondrial 
GSH redox cycle in maintaining a healthy antioxidant system, and 
consequently, on hydrogen peroxide homeostasis.  
NADPH sources 
Since the regeneration of GSSG or oxidized Trx is dependent on reducing 
equivalents, hence pathways that modulate NADPH may indirectly affect 
antioxidant efficiency. Several sources contribute to the regeneration of NADPH 
in mitochondria, including the NADP+-dependent isocitrate dehydrogenase 
(IDH2), malic enzyme, and the nicotinamide nucleotide transhydrogenase (Nnt) 
[45]. The redox level of mitochondrial NADP is normally more than 95% 
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reduced, about half of which is uncoupler sensitive [46]. Thus, the uncoupler-
sensitive part is consistent with Nnt-generated NADPH, even though 
contributions by other sources cannot be excluded. Moreover, the relevance of 
mitochondrial NADPH sources is highlighted by the observation that the diabetic 
characteristics of C57BL/6J mice, such as glucose intolerance and reduced 
insulin secretion, are primarily due to an impaired transhydrogenase activity 
[47]. In this context, it should be pointed out that transhydrogenase is strongly 
inhibited by fatty acyl CoA, especially long chain acyl CoA, which may further 
suppress Nnt activity in the presence of a high cellular content of fatty acids, 
typical of a pre-diabetic condition [46, 48]. On the other hand, IDH2 catalyzes 
the oxidative decarboxylation of isocitrate into 2-oxoglutarate generating 
NADPH or NADH from NADP+ or NAD+, respectively. IDH2 can be inactivated 
by peroxynitrite, as shown recently by alcohol feeding resulting in decreased 
NADPH equivalents and subsequent GSH defense [49]. In line with these 
observations, it has been reported that IDH2 silencing sensitizes tumor cells to 
apoptosis in response to various stimuli, including brefeldin A, anticancer drugs, 
tumor necrosis factor-α, doxorubicin, actinomycin D and etoposide [50, 51]. 
Whether this outcome is related directly to perturbation of NADPH equivalents 
or to the generation of oncometabolites such (R)-2-hydroxyglutarate and 
subsequent alterations in hypoxia signaling and DNA methylation remains to be 
established [52]. 
2. mGSH Transport 
Despite the high GSH concentration existing in mitochondrial matrix, GSH is not 
synthesized de novo as mitochondria lack the enzymes required for the 
synthesis of GSH from its constituent aminoacids. Therefore, mitochondrial 
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GSH arises from the cytosol GSH by the activity of specific carriers [7]. 
Furthermore, GSH has an overall negative charge at physiological pH and 
mitochondria exhibit a large negative membrane potential; consequently, 
although GSH can cross easily the mitochondrial outer membrane (MOM) 
through porin channels its transport into mitochondrial matrix cannot be 
explained by simple diffusion. Indeed, recent findings using dynamic oxidant 
recovery assays together with GSH-specific fluorescent reporters, determined 
the free communication of GSH pools between cytosol and the 
intermitochondrial space (IMS). In contrast, no appreciable communication was 
observed between the GSH pools of the IMS and matrix [53].  
mGSH transport in kidney 
Previously, two mitochondrial inner membrane (MIM) anion carriers were 
identified in kidney and liver as GSH transporters, the 2-oxoglutarate carrier 
(OGC; Slc25a11) and the dicarboxylate carrier (DIC; Slc25a10) [54-57]. These 
antiport carriers, OGC and DIC, import cytosolic GSH into mitochondria in 
exchange for 2-oxoglutarate (2-OG) and inorganic phosphate (Pi2–), 
respectively [2]. In reference to the presence of mGSH carriers in kidney, Lash 
et al. [58] showed that overexpression of the rat kidney DIC carrier in a cell line 
derived from rat kidney proximal tubules (NRK-52E) increased the mGSH pool 
size 2- to 10-fold with respect to wild-type NRK-52E cells, thus demonstrating a 
role for this carrier in the mitochondrial transport of GSH in exchange with 
inorganic phosphate. Moreover, evidence for a role of the OGC carrier as a 
GSH transporter was based on substrate specificity and pattern of inhibition in 
rabbit kidney mitochondria and in a partially purified preparation of 
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mitochondrial transporters from kidney mitoplasts reconstituted in 
proteoliposomes [54, 55].  
mGSH transport in liver 
Additionally, the functional expression of the hepatic OGC in Xenopus laevis, 
demonstrated transport of reduced GSH in a phenylsuccinate-sensitive manner 
[56], further confirming the suggestion that the OGC contributes to the transport 
of GSH in liver mitochondria. In contrast to OGC, no clear evidence for DIC in 
the transport of mitochondrial GSH was found in rat liver [56]. For instance, the 
functional expression in oocytes microinjected with the DIC cRNA from rat liver 
did not result in significant GSH transport activity [56].  A key insight from this 
study was the fact that the activity of OGC was sensitive to altered membrane 
physical properties, in line with what has been reported for the mitochondrial 
transport of GSH [2]. The initial uptake rate of 2-oxoglutarate was reduced in 
mitochondria from alcohol-fed rat livers, an effect that was not accompanied by 
an alcohol-induced decrease in the OGC messenger RNA levels but rather by 
changes in mitochondrial membrane dynamics induced by alcohol. The 
fluidization of mitochondria by the fatty acid derivative A2C, a fluidizing 
molecule, restored the initial transport rate of both GSH and 2-oxoglutarate.  
Two components have been described for mGSH transport in rat liver 
mitochondria, at external GSH levels of less than 1 mM, GSH is transported into 
the mitochondrial matrix by a high-affinity low-capacity component (Km, 
approximately 60 microM; Vmax, approximately 0.5 nmol/min per mg of protein), 
which is saturated at levels of 1-2 mM and stimulated by ATP, and a low-affinity 
high capacity (Km, approximately 5.4 mM; Vmax, approximately 5.9 nmol/min per 
mg of protein) and is stimulated by ATP and inhibited by glutamate and 
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protonophores that collapse the protonmotive force  [59]. Consistent with these 
findings in liver mitochondria, the transport of GSH into rat kidney mitochondria 
required ATP production, as oligomycin in the presence of ATP inhibited GSH 
uptake [54], indicating the dependence of the mitochondrial transport of GSH on 
the protonmotive force. However, ATP did not stimulate the transport of GSH in 
kidney mitochondria from fed rats [54]. This discrepancy with respect to 
previous observations in rat liver mitochondria may relate to the energized state 
of mitochondria (fasted vs. fed). 
Kinetic analyses of 2-oxoglutarate transport in rat liver mitochondria indicated 
the presence of a single Michaelis-Menten component with kinetic parameters 
in the range of those reported previously for kidney mitochondria [54-56]. This 
feature is in contrast to the 2 components for mitochondrial GSH transport [2, 7, 
59]. The kinetic parameter of the low-affinity component of GSH transport and 
that of 2-oxoglutarate are similar, both showing a Michaelis constant in the 
mmol/L range and a similar maximum velocity [56]. These findings suggest that 
the OGC accounts for the low-affinity high capacity of GSH transport in liver 
mitochondria, and imply that the nature of the high affinity GSH transporter 
remains to be identified. However, whether these carriers also participate in the 
efflux of mGSH in exchange for cytosolic GSH is unknown. In line with this, 
intriguing findings indicated that inhibition of OGC or DIC by phenylsuccinate or 
butylmalonate in kidney HRK523 cells resulted in increased rather than 
decreased mGSH levels, suggesting the possibility for OGC/DIC to mediate 
GSH efflux from mitochondria [60]. Moreover, as opposed to release of GSSG 
from cells, recent studies argue that GSSG does not efflux out of mitochondria, 
implying that under oxidant conditions, the accumulation of GSSG contributes to 
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mitochondrial protein glutathionylation and subsequent impaired function [61]. In 
addition, since regeneration of GSH in mitochondria is dependent on reduced 
environment and NADPH availability, mGSH is highly dependent on the 
respiratory substrates used to produce NADPH [61], and on the availability of 
the reduced nucleotide cofactor.  
mGSH transport in brain 
However little is known about mGSH transport in organs different from liver and 
kidney. In brain, some studies have examined the mechanisms responsible for 
mitochondrial GSH transport. In one report, the properties of GSH transport in 
isolated rat brain mitochondria seemed to be greatly different from those 
reported previously for mitochondria from kidney, and influenced most by 
inhibitors of the tricarboxylate carrier rather than OGC or DIC [62]. However, in 
mouse brain mitochondria another study showed that OGC and DIC are both 
expressed in cortical neurons and astrocytes [63]. In addition, butylmalonate, an 
inhibitor of DIC, significantly decreased mGSH, suggesting DIC as the major 
GSH transporter in mouse cerebral cortical mitochondria [63]. Moreover, a role 
for UCP2 in the transport of mitochondrial GSH has been described in neurons, 
suggesting that the transport of protons back into the matrix by UCP2 may favor 
the movement of GSH [64]. These studies suggest that, in the brain, multiple 
MIM anion transporters might be involved in mGSH transport, however, 
essentially nothing is known about how the function of these carriers is 
regulated. An interesting recent study, suggested the participation of Bcl-2 as a 
binding partner for mGSH, consequently enhancing its affinity for the OGC [46]. 
In this context, the binding of recombinant Bcl-2 to GSH in vitro, was 
antagonized by the Bcl-2 homology-3 domain (BH3) mimetics HA14-1 and 
Mari et al,  BBAGEN-12-0409-R 
 16
compound 6, as well as the BH3-only protein, Bim [65]. Bcl-2 and OGC appear 
to act in a coordinated manner to increase the mGSH pool and to enhance the 
resistance of neurons to mitochondrial oxidative stress. Therefore, the 
antioxidant-like function attributed to Bcl-2 could in part depend on its potential 
to regulate the cellular glutathione status [57]. 
Unlike 2-OG and DIC carriers, the evidence for these alternative carriers and 
regulators in the transport of mGSH in hepatic liver mitochondria remains to be 
established. A key feature of the transport of GSH through OGC is its strict 
dependence on appropriate membrane dynamics, which is determined by fatty 
acid composition and the cholesterol/phospholipid molar ratio [56, 66]. 
Cholesterol is a critical component of membranes with key structural and 
functional roles [67]. Compared to plasma membrane, mitochondria are much 
less enriched in cholesterol with estimates of about 3–5% of the total 
cholesterol cell load [68]. This restricted pool of cholesterol in mitochondria, 
however, plays a fundamental physiological role in the synthesis of bile acids in 
hepatocytes or steroidogenic hormones in specialized tissues [69]. Given the 
role of cholesterol in the regulation of membrane dynamics and physical 
properties, the synthesis and supply of membrane cholesterol is highly 
regulated under physiological conditions. Cholesterol is known to regulate 
membrane organization [55]. In this regard, it has been shown that cholesterol 
loading in mitochondria results in increased membrane order parameter which 
negatively impacts specific membrane carriers, such as the GSH transport 
system without effect in others, including the S-adenosyl-L-methionine transport 
system [70]. Functional expression studies in Xenopus laevis oocytes provided 
clear evidence that the OGC is highly sensitive to mitochondrial membrane 
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fluidity loss induced by cholesterol loading [56]. Thus, one of the functional 
consequences of mitochondrial cholesterol enrichment is the impairment of 
mGSH transport which results in depletion of GSH in the mitochondrial matrix. 
This selective pool of GSH has been shown to play a key role in controlling cell 
susceptibility to oxidative stress, Ca2+ overload, TNF/Fas, and hypoxia [71-76], 
and its depletion has been shown to contribute to a number of pathologies, 
some of which will be covered below [2, 8, 77-80].  
 
3. mGSH and Cell Death. 
Mitochondria play a central role in various forms of cell death, which are 
characterized by differential biochemical features, with predominant forms 
including apoptosis (caspase-dependent and independent), or necrosis. 
Besides amplifying and mediating extrinsic apoptotic pathways, mitochondria 
also play a central role in the integration and propagation of death signals 
originating from inside the cell such as DNA damage, oxidative stress, 
starvation, as well as those induced by radiation or chemotherapy [81-85]. 
Apoptosis, also known as programmed cell death, describes a particular mode 
of cell death that is characterized by a series of biochemical events that lead to 
a variety of morphological changes, including cell shrinkage, membrane 
blebbing or budding, nuclear fragmentation, chromatin condensation, and 
chromosomal DNA fragmentation. Ultimately, the cell is fragmented into 
compact membrane-enclosed structures, called “apoptotic bodies” which 
contain cytosol, condensed chromatin, and organelles. Apoptotic bodies are 
ingested by neighboring cells and phagocytes, preventing inflammation and 
tissue damage that might ensue upon cell lysis. Apoptosis is induced via two 
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main routes involving either the mitochondria (the intrinsic pathway) or the 
activation of death receptors (the extrinsic pathway) (Figure 2). Both pathways 
converge to induce the activation of caspases, the final executioners of cell 
death [86-88]. In the extrinsic pathway, or “death receptor” pathway, ligand 
binding results in the formation of a multiprotein complex named death-inducing 
signaling complex (DISC) and the activation of procaspase-8 [86, 87]. Active 
caspase-8 then processes downstream effector caspases, such as caspase-3, 
which subsequently cleave specific substrates resulting in cell death. Cells 
harboring the capacity to induce such direct and mainly caspase-dependent 
apoptosis pathways are called type I cells.  However, in type II cells, the signal 
generated from the activated receptor does not results in strong caspase 
activation to execute cell death. In this case, the signal needs to be amplified 
via mitochondria-dependent apoptotic pathways. The link between the caspase 
signaling cascade and the mitochondria is provided by the Bcl-2 family member 
Bid. Bid is cleaved by caspase-8 and in its truncated form (tBID) translocates to 
the mitochondria where it induces the translocation, oligomerization, and 
insertion of other Bcl2-family members such as Bax and/or Bak into the MOM 
[89], resulting in the integration of the extrinsic and intrinsic pathways, the latter 
also known as the mitochondrial pathway (Figure 2). This is followed by 
mitochondrial outer membrane permeabilization (MOMP) and release of several 
proteins from the mitochondrial intermembrane space, including cytochrome c. 
Once cytochrome c is released it binds to monomeric Apaf-1 which then, in a 
dATP-dependent conformational change, oligomerizes to assemble the 
apoptosome, a complex that triggers the activation of the initiator procaspase-9. 
Activated caspase-9 subsequently initiates a caspase cascade involving 
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downstream effector caspases, such as caspase-3, ultimately resulting in the 
execution of apoptosis [90]. Similarly, during the execution of the intrinsic or 
mitochondrial pathway death signals originating from inside the cell, such as 
DNA damage, oxidative stress, starvation, as well as those induced by 
chemotherapeutic drugs, converge in the mitochondria at the level of 
translocation of Bax/Bak into the outer mitochondrial membrane, triggering 
MOMP and the consequent release of cytochrome c to the cytosol committing 
the cell to apoptosis (Figure 2) [82, 83]. In addition to cytochrome c, other 
proteins from IMS are released to assist or potentiate apoptosis. For instance, 
Smac/Diablo antagonizes inhibitors of caspases, thereby enhancing caspase 
activation and apoptosis. Through mitochondria to nuclei translocation, AIF 
insures caspase-independent mitochondria-mediated apoptosis inducing 
chromatin condensation and DNA fragmentation [91]. 
As opposed to apoptosis, necrosis is a morphologically distinct form of cell 
death responsible for irreversible tissue destruction due to bioenergetic failure 
and oxidative damage. The fundamental difference to apoptosis is the rapid loss 
of cellular membrane potentials due to energy depletion and ion pump/channel 
failures, leading to swelling, rupture and cytolysis. Rather than being a passive 
event, necrosis has emerged as a controlled cell death that induces an 
inflammatory response to stimulate tissue repair by releasing specific factors 
from dying cells such as HMGB1 and HDGF [92]. Necrosis is dependent on the 
mitochondrial permeability transition pore (mPT), a channel complex that spans 
outer and inner mitochondrial membranes at points of contact [93]. mPT is a 
regulated nonselective water and soluble-passing protein complex whose 
molecular identity is still debated. It can encompass voltage-dependent anion 
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channel (VDAC) across the MOM and adenine nucleotide translocase (ANT) 
across the MIM [91, 94]. In contrast to VDAC and ANT, the prolyl isomerase 
cyclophilin D in the mitochondrial matrix is an essential regulator of mPT and 
the only genetically proven indispensable mPT component [95-98]. Upon 
oxidative stress, sudden mPT causes massive ion influx that dissipates 
mitochondrial membrane potential and shuts down oxidative phosphorylation, 
ATP production, and ROS overgeneration. Concomitantly, water influx causes 
matrix swelling, rupture of the rigid MOM and release of apoptogenic proteins 
sequestered in IMS. Although cytochrome c is released, apoptotic cell death 
under mPT is inhibited due to energetic failure and ATP exhaustion and 
oxidative stress-mediated caspase inactivation. Thus, although mitochondria 
are is the strategic center in the control of cell death, the outcome of MOMP 
leading to apoptosis or necrosis is determined by the nature and intensity of 
stimuli and whether mPT is engage [99]. Thus, the mPT induces cell death, and 
depending on the level of cellular ATP, as ATP is required for the efficient 
assembly of the apoptosome and/or the extent of ROS generation, apoptosis 
and/or necrosis will ensue [83, 91, 100-102]. Consequently, understanding the 
mechanisms leading to MOMP is essential for designing strategies to control 
cell death.  
In this regard, although the field has mainly focused on the role of Bcl-2 family 
members in the regulation of MOMP and cell death [91, 100, 103], an 
increasing body of evidence points to a key role of lipids in the regulation of 
MOMP, cytochrome c release and cell death susceptibility [104]. Recent 
studies, reported a key role for sphingolipids, particularly sphingosine 1-
phosphate and hexedecenal in the regulation of mitochondrial pathway of 
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apoptosis induced by Bax/Bak [105]. Moreover, cardiolipin, an anionic 
phospholipid of the mitochondrial inner membrane, has emerged as a regulator 
of apoptosis by playing an important role in cytochrome c release from 
mitochondria. At physiological pH, cytochrome c is electrostatically bound with 
cardiolipin. Additionally, this binding is enhanced by the insertion of one chain of 
cardiolipin into a hydrophobic channel of cytochrome c, while the other 
cardiolipin acyl chains remain in the membrane, therefore anchoring 
cytochrome c to the mitochondrial membrane [68, 104, 106]. Hence, after 
apoptotic stimulus, ROS in mitochondria can oxidize cardiolipin, and oxidized 
cardiolipin has lower affinity for cytochrome c, resulting in cytochrome c 
detachment from the mitochondrial inner membrane (Figure 3) [68, 76, 106, 
107]. In addition, it has been described that oxidized cardiolipin modulates the 
biophysical properties of MOMP to allow oligomerized Bax to insert and 
permeabilize the mitochondrial outer membrane [68, 76, 108]. Altogether, these 
results support the hypothesis that cardiolipin is a key upstream target in 
mitochondria-dependent apoptosis. Despite only a small fraction of cytochrome 
c being bound to cardiolipin (about 15%), the oxidation of this lipid is thought to 
impact the mobilization of cytochrome c from the mitochondria, although the 
relevance of this step in the release of cytochrome c to the cytosol is 
controversial. Since mitochondrial ROS contribute to cardiolipin oxidation and 
are controlled by antioxidants such as GSH [2, 76], mGSH arises as an 
important modulator of apoptotic cell death by indirectly controlling the redox 
state of cardiolipin [68, 76]. Accordingly, mGSH depletion due to alcohol-
mediated alteration in mitochondrial membrane dynamics underlies the 
susceptibility of hepatocytes from alcohol-fed models to tumor necrosis factor 
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(TNF) [109], and in nutritional and genetic models of hepatic steatosis [75, 110], 
mGSH depletion occurs due to the enrichment of mitochondria in free 
cholesterol, resulting in decreased mitochondrial membrane fluidity [75]. Of 
importance, this effect was reproduced after selectively depleting mGSH in 
“healthy” hepatocytes by means of using 3-hydroxy-4-pentenoate (HP) which 
undergoes mitochondrial biotransformation into a Michael electrophile followed 
by its conjugation with GSH in the mitochondrial matrix [111], thereby 
sensitizing them to the inflammatory cytokine TNF [6, 76, 112, 113]. Moreover, 
the susceptibility to TNF after mGSH depletion, and subsequent cardiolipin 
oxidation was observed despite unimpaired GPx, Trx2, and Prx3, thus 
highlighting the relevance of mGSH in cell protection under oxidative stress 
[76]. In addition, similar sensitization by mGSH depletion was observed in 
neurons and glia cell lines challenged with amyloid-beta mediated cell death 
[80]. In addition, in cerebellar granule neurons, while direct depletion of 
mitochondrial and cytoplasmic GSH resulted in increased generation of ROS, 
decrease of the mPT, rapid loss of mitochondrial function, and cell death 
without apoptotic features, these effects were not observed if mGSH was 
relatively maintained [114]. Additionally, in astrocytes, a selective loss of 
mGSH, as a result of treatment with ethacrynic acid, increased cell vulnerability 
to peroxynitrite and hydrogen peroxide whereas protection was afforded by prior 
elevation of the mGSH pool by GSH ethyl ester, thus providing new direct 
evidence for the importance of mGSH in protection against necrotic cell death 
induced by reactive oxygen and nitrogen species [115]. Overall, these studies in 
brain cells indicate that the role of mGSH in regulating cell death susceptibility is 
not tissue specific. mGSH not only regulates cell death susceptibility but the 
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outcome of cell death, that is necrosis or apoptosis. In principle, thiol redox 
status regulate mPT and enhanced ROS generation can target critical cysteine 
residues in cyclophilin D, implying that mGSH depletion would favor mPT via 
redox pathways targeting mPT components. In addition, through modulation of 
cardiolipin redox state, mGSH can also regulate MOMP and hence the release 
of apoptogenic proteins. 
mGSH depletion has also been associated to apoptosis or autophagy induced 
by chemotherapeutic drugs. For instance, the novel triterpenoid methyl-2-
cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me) potently induced 
cytotoxicity in imatinib-resistant myeloid leukemia cells. The low-dose effects of 
CDDO-Me were mainly associated with inhibition of mitochondrial oxygen 
consumption, whereas the cytotoxic effects appear to be mediated by a rapid 
and selective depletion of mGSH that accompanied the increased generation of 
ROS and mitochondrial dysfunction. Interestingly, the toxic effects of CDDO-Me 
were followed by rapid autophagocytosis of intracellular organelles or the 
externalization of phosphatidylserine in different cell types [116, 117], indicating 
that alterations in mitochondrial function by CDDO-Me can result in autophagy 
or apoptosis of chronic myeloid leukemia. These observations have also been 
extended to ovarian cancer cells [118]. Similarly, β-phenethyl isothiocyanate 
(PEITC), a natural product with potent anticancer activity against human 
leukemia cells, caused a rapid depletion of mitochondrial GSH and a significant 
elevation of ROS and nitric oxide, induced a disruption of the mitochondrial 
electron transport complex I, and a significant suppression of mitochondrial 
respiration that resulted in cytotoxicity in leukemia cells [119]. Taken 
collectively, these findings provide a basis for developing new therapeutic 
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strategies to effectively cancer cells by using drugs that selectively deplete 
mGSH stores.  
 
4. mGSH in pathology 
Examples for the contribution of mGSH to different diseases have increased 
over the years. In many pathological settings mGSH depletion is both the 
consequence of disease progression and the cause of organ failure, and in 
most cases related to cholesterol-mediated changes in membrane dynamics. 
Indeed, mitochondrial cholesterol has emerged as an important modulator of 
MOMP in response to apoptotic stimuli underlying the importance of this lipid in 
disease pathogenesis, including alcoholic and nonalcoholic steatohepatitis, 
Alzheimer's disease or hepatocellular carcinoma [68, 69, 75, 120] by regulating 
mGSH transport, mGSH homeostasis and subsequent protection of cardiolipin 
from peroxidation (Figure 3). 
In the following sections we will briefly cover the best characterized examples of 
the role of mGSH depletion in disease pathogenesis. 
Neurological disorders 
The brain is particularly vulnerable to oxidative damage because of its high 
oxygen utilization, content of oxidizable polyunsaturated fatty acids, and 
presence of redox-active metals (Cu, Fe). Oxidative stress increases with age 
and therefore it can be considered as an important causative factor in several 
neurodegenerative disorders, such as Alzheimer disease (AD), Parkinson 
disease (PD) or Huntington disease (HD). The pathogenesis of AD is not clear 
and two main theories have been put forward, including the accumulation of 
toxic amyloid plaques and the aberrant phosphorylation of tau proteins. 
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Although evidence has been gathered in favor of both, a recent study provides 
strong support for the amyloidogenic theory of AD [121].  A rare genetic variant 
identified in Scandinavians resulting in lower amyloidogenic processing of 
amyloid β-precursor protein (APP) defended elderly population against AD 
[121].  The brains of Alzheimer disease patients show a significant extent of 
oxidative damage associated with marked accumulation of amyloid-β-peptide 
(Aβ), the main constituent of senile plaques in brain [122, 123]. Epidemiological, 
genetic and biochemical studies have identified cholesterol, Aβ and 
mitochondria as key factors in AD pathogenesis. However, the putative 
participation of cholesterol in AD has been limited to the amyloidogenic 
processing of APP at the plasma membrane, particularly in lipid rafts where 
APP is processed by β-secretase 1 to generate Aβ. Of interest, current 
evidence indicates that targeting of Aβ to intracellular sites, most notably 
mitochondria, causes oxidative stress, mitochondrial dysfunction and cell death 
[124, 125]. Not only Aβ may cause mitochondrial ROS production, but also it is 
becoming clear that oxidative damage occurs early in the AD brain, even before 
the onset of significant plaque pathology [126]. Recent findings tested the 
hypothesis that mitochondrial cholesterol modulated Aβ neurotoxicity and AD 
pathology [68]. Using genetic models of cholesterol loading, it was found that 
mitochondrial cholesterol sensitized neurons to Aβ in vitro, while 
intracerebroventricular Aβ infusion resulted in neuroinflammation and 
neurotoxicity. Isolated mitochondria from brain or cortical neurons of transgenic 
mice overexpressing SREBP-2 (sterol regulatory element binding protein 2) or 
NPC1 (Niemann-Pick type C1) knock-out mice exhibited mitochondrial 
cholesterol accumulation, mGSH depletion and increased susceptibility to Aβ-
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induced oxidative stress and release of apoptogenic proteins. Similar findings 
were observed in pharmacologically GSH-restricted rat brain mitochondria, 
while selective mGSH depletion sensitized human neuronal and glial cell lines 
to Aβ-mediated cell death [80]. Two lines of evidence indicate that the mGSH 
depletion specifically accounted for the increased susceptibility to Aβ observed 
in these genetic models. First, the sensitivity of rat brain mitochondria to Aβ-
mediated oxidative stress and release of intermembrane apoptotic proteins was 
dependent on the levels of mGSH. Second, selective pharmacological depletion 
of mGSH with the sparing of cytosol GSH in human neuroblastoma and glial 
cells sensitized to Aβ-mediated cell death. Moreover, in vivo 
intracerebroventricular human Aβ delivery colocalized with mitochondria 
resulting in oxidative stress, neuroinflammation and neuronal damage that were 
enhanced in Tg-SREBP-2 mice and prevented upon mGSH recovery by GSH 
ethyl ester coinfusion [80]. Hence these findings expand the role of cholesterol 
and mGSH depletion in Aβ neurotoxicity. 
In addition, significant biological changes, related to oxidative stress, have been 
found in brain tissue of individuals affected by PD. In particular, data from 
postmortem studies of brains from patients with PD suggest that oxidative 
stress plays a role in neural degeneration of the pigmented dopaminergic 
neurons in the substantia nigra. Moreover, the normal metabolism of dopamine 
can generate free radicals and other ROS. Furthermore, in the human SNpc the 
autooxidation of dopamine leads to neuromelanin and can generate quinone 
and semiquinone species and ROS [127, 128]. According to postmortem 
studies, GSH levels in the SNpc of PD patients are remarkably lower than those 
of healthy subjects (60% compared to control subjects) while oxidized 
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glutathione (GSSG) levels are slightly increased. GSH loss in PD is also 
accompanied by a reduction in mitochondrial complex I activity, which is 
regionally selective for the substantia nigra in PD and does not occur in related 
basal ganglia degenerative disorders. Consistent with these findings, we have 
shown that selective mGSH depletion mice sensitized to in vivo injection of 3-
nitropropionic acid (3-NP), a mitochondrial toxin used extensively as a model of 
HD [129]. 3-NP delivery into the striatum of caveolin-1 knockout mice resulted in 
extensive areas of degeneration and cell death compared to wild type mice. 
Moreover, following occlusion of the middle cerebral artery in rat brain, early 
and selective loss of mGSH has been reported [130]. The mGSH depletion 
showed an apparent association with the tissue damage that developed during 
subsequent reperfusion, suggesting that it could be an important determinant of 
susceptibility to cell loss. In fact, brain infusion of GSH-monoethyl ester (GSH-
EE) increased cellular GSH and was particularly effective in replenishing the 
mitochondrial pool, and reduced infarct size from 46% of the total ischaemic 
hemisphere in saline-treated animals to 16% following GSH-EE treatment, thus 
providing neuroprotection following transient focal cerebral ischaemia [131]. 
Thus, these findings illustrate the relevance in searching for optimal means to 
deliver GSH precursors and prodrugs to the central nervous system as a 
strategy for neurodegeneration [132]. However, an additional challenge in this 
aim is to satisfactorily reach mitochondria to increase the mGSH pool despite 
impaired transport due to loss of membrane physical properties. 
Liver diseases 
The implication of oxidative stress in liver diseases has been well characterized, 
playing a role in diseases such as viral hepatitis, metabolic liver diseases, 
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ischemia/reperfusion injury and drug toxicity. Steatohepatitis, however, is one of 
the best characterized examples where mGSH depletion plays an important role 
in disease pathogenesis. Steatohepatitis represents an advanced stage in the 
spectrum of fatty liver disease that encompasses alcoholic (ASH) and non-
alcoholic steatohepatitis (NASH), two of the most common forms of liver 
disease worldwide [112, 133]. Although the primary etiology of ASH and NASH 
is different, the pathology of ASH is remarkably similar to that of NASH, 
suggesting some common pathogenic mechanism. These two diseases have 
almost identical histology characterized by steatosis (macrovesicular > 
microvesicular), mixed lobular inflammation with scattered polymorphonuclear 
leukocytes as well as mononuclear cells and hepatocellular cell death due to 
sensitivity to oxidative stress [112, 133-136]. The pathogenesis of ASH and 
NASH is currently unknown. A prevalent view according to the two hit 
hypothesis is that fat infiltration in hepatocytes sensitizes to secondary hits, 
promoting hepatocellular death, inflammation and fibrosis reflecting disease 
progression. However, we postulated that the type rather than the amount of fat 
plays a critical role in the transition from steatosis to ASH/NASH. In line with this 
hypothesis, previous studies have shown that chronic alcohol feeding in various 
models results in the depletion of mGSH due to cholesterol loading in 
mitochondria [6, 109, 110, 112, 137, 138] and that strategies aimed to correct 
the loss of mitochondrial membrane fluidity restore the mitochondrial transport 
of GSH and replenish the mGSH pool in alcohol-fed models. This is of 
relevance in TNF susceptibility as mGSH depletion primes mitochondria to 
TNF-mediated mitochondrial outer membrane permeabilization by Bax through 
cardiolipin peroxidation [76]. The mechanisms of alcohol-induced lipogenesis 
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involved endoplasmic reticulum (ER) stress, which triggers the activation of 
transcription factors SREBP-1c and SREBP-2, resulting in de novo synthesis of 
fatty acids and cholesterol [133]. Altered alcohol-induced ER stress, in turn, 
involved perturbed methionine metabolism and subsequent 
hyperhomocysteinemia [139]. Indeed, supplementing alcohol-fed mice with 
betaine prevented hyperhomocysteinemia and subsequent ER stress [140]. In 
line with these findings, we observed that tauroursodeoxycholic acid, a chemical 
chaperone shown to prevent ER stress in ob/ob mice [141], restored mGSH 
pool in alcohol fed rats [137] and blocked alcohol-induced ER stress 
(Fernandez et al, unpublished data). Alcohol-induced mitochondrial cholesterol 
trafficking is mediated by alcohol-induced upregulation of StAR, the founding 
member of StAR family of a mitochondrial transporting cholesterol proteins, 
whose expression is regulated by ER stress (Fernandez et al, unpublished 
data). 
Similarly, using nutritional and genetic models of hepatic steatosis, we have 
described that free cholesterol loading, but not free fatty acids or triglycerides, 
sensitizes to TNF- and Fas-induced steatohepatitis [75]. The mechanism 
involved cholesterol-mediated mGSH depletion as mGSH replenishment by S-
adenosyl-L-methionine or GSH ethyl ester protected mice fed high cholesterol 
diet against LPS-induced liver injury. Although mGSH depletion has been 
observed in models and patients with NASH [142], other mitochondrial 
antioxidant defenses are also affected, including the activity of SOD2. This 
outcome contributes to increased superoxide anion and subsequent 
peroxynitrite levels that target mitochondrial proteins. Therefore, strategies such 
as the use of SOD mimetics aimed to improve SOD-2 activity may be of 
Mari et al,  BBAGEN-12-0409-R 
 30
relevance in steatohepatitis. However, the use of SOD mimetics in the face of 
coexisting mGSH depletion leads to increased hydrogen peroxide, contributing 
to hepatocellular injury and inflammation in models of nutritional steatohepatitis 
[143]. These findings widen the concept of oxidative stress implying the 
importance of a delicate equilibrium between antioxidants to prevent 
accumulation of reactive species. In addition, the concept that oxidative stress 
does not necessarily reflect the unbalance between ROS and antioxidants helps 
explain the failure of antioxidant treatment so far in human liver diseases. Data 
and models described here could offer an explanation for the important 
discrepancy between the overwhelming evidence for an important role of ROS 
and the common clinical failure of trials. 
Other pathological settings 
In humans, caveolin-1 (CAV1) mutations result in lipodystrophy, cell 
transformation, and cancer. Moreover, CAV1 gene-disrupted mice exhibit 
cardiovascular diseases, diabetes, cancer, atherosclerosis, and pulmonary 
fibrosis. The mechanisms underlying these disparate effects are unknown, but 
there are a variety of mild phenotypes that link the loss of CAV function with 
unrelated diseases [144-146], which are likely explained by metabolic failure 
and oxidative stress [147]. Caveolae are distinctive invaginations of the plasma 
membrane with reduced fluidity, reflecting cholesterol accumulation, and are 
present in most mammalian cells [148, 149]. Caveolins (CAVs), integrated 
plasma membrane proteins, are essential components of caveolae, and 
complex signaling regulators with numerous partners and whose activity is 
highly dependent on cellular context [150, 151]. CAV-1 proteins bind cholesterol 
with high affinity [152], and CAV's ability to move between these compartments 
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might contribute to regulation of cholesterol fluxes and distributions within cells 
[148, 152, 153].  
In a recent study, it has been uncovered that loss of CAV1 alters mitochondrial 
function, which may provide a single underlying mechanism for the myriad of 
pathologies related to CAV1 mutations [129]. Without CAV1, free cholesterol 
accumulates in mitochondrial membranes, increasing membrane viscosity and 
reducing efficiency of the respiratory chain and depleting mGSH [121]. Indeed, 
this mitochondrial dysfunction predisposes CAV1-deficient animals to 
mitochondrial-related diseases such as steatohepatitis and neurodegeneration. 
CAV1 deficiency impairs mitochondria by promoting an increased influx and 
accumulation of free cholesterol in mitochondrial membranes. Although in this 
particular study only the effect of the mitochondrial failure caused by CAV1 
deficiency in liver, brain, and fibroblasts was addressed, naturally occurring 
CAV1 deficiencies in humans cause disease in other tissues as well [150]. In 
the lung, for instance, CAV1 is highly expressed and a recent study has been 
reported that CAV1 deletion results in major functional aberrations, suggesting 
that caveolin-1 may be crucial to lung homeostasis and development [154]. 
Furthermore, generation of mutant mice that under-express CAV1 results in 
severe functional distortion with phenotypes covering the entire spectrum of 
known lung diseases, including pulmonary hypertension, fibrosis, increased 
endothelial permeability, and immune defects [155]. The contribution, however, 
of mitochondrial cholesterol or mGSH in the lung pathogenesis in CAV1 
deficient animals remains to be elucidated. 
As described above, mitochondrial oxidative stress is at the heart of many 
pathological settings. Since lipophilic cations accumulate in mitochondria, the 
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covalent attachment of a neutral bioactive compound to a lipophilic cation 
should lead to its selective delivery to mitochondria. In this regard, alkyl-
triphenylphosphonium (TPP) cations are an excellent tool for the delivery of 
compounds to mitochondria as they preferentially accumulate (about hundred-
fold) within mitochondria in cells making it possible to deliver a wide range of 
mitochondria-targeted lipophilic TPP cations [156, 157]. Murphy and coworkers 
have extended this concept to develop a series of cationic antioxidants that 
include derivatives of the endogenous antioxidants ubiquinol (MitoQ), alpha-
tocopherol (MitoVit E), and of the synthetic spin trap PBN (MitoPBN) [156]. 
These compounds have been found to block oxidative damage in isolated 
mitochondria and cells far more effectively than untargeted antioxidant analogs 
due to their concentration within mitochondria, and its oral administration leads 
to their accumulation in the brain, heart, muscle and liver [143, 156]. In fact, 
MitoQ has been used in a range of in vivo studies, in rats and mice, and in two 
phase II human trials demonstrating that it can be safely delivered to patients 
with promising results, lending further support that mitochondria-targeted 
antioxidants may be applicable to a wide range of human pathologies that 
involve mitochondrial oxidative damage [158].  
 
5. Final Remarks 
Mitochondria play an essential role in maintaining cells alive by providing the 
energy needed for multiple signaling cascades and functions. The consumption 
of molecular oxygen in the respiratory chain is not only the driving force for the 
ATP synthesis required for cell viability, but also the source of ROS that target 
mitochondrial and extramitochondrial processes. Mitochondrial GSH plays a 
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critical role to control the damaging effects of mitochondrial generated ROS, 
and hence its regulation modulates cell death susceptibility and disease 
progression. In particular, understanding the regulation of mGSH transport may 
provide novel opportunities for treatment of liver diseases and 
neurodegeneration. In this regard, evidence has shown that mGSH depletion 
contributes to susceptibility of hepatocytes or neurons to stimuli that generate 
oxidative stress including inflammatory cytokines, hypoxia or amyloid β-peptide. 
Since a key feature of mGSH is that its import from cytosol depends on 
appropriate mitochondrial membrane physical properties, strategies aimed to 
increase mGSH by boosting cytosol GSH (e.g. NAC) may not be an optimal 
approach for steatohepatitis or Alzheimer disease, as it would result in mainly 
increasing cytosol GSH without replenishing mGSH levels. In this regard, 
targeting mitochondrial cholesterol trafficking or using membrane permeable 
GSH prodrugs may constitute an efficient approach to boost mGSH. Thus, 
these data illustrate the importance of GSH in mitochondria in cell death 
regulation and in disease progression, indicating that a better understanding of 
mGSH transport and regulation may have important implications in disease 
pathogenesis. 
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FIGURE LEGENDS 
Figure 1. Mitochondrial antioxidant defense system. Scheme of the different 
reactions that take place in the mitochondria to cope with the oxidative stress 
derived from the presence of superoxide anion, hydrogen peroxide, and 
hydroxyl radical. A, Removal of H2O2, and B, elimination of hydroxyl radical 
generated through the Fenton reaction. GSH peroxidase (Gpx), GSSG-
reductase (GR); GSSG, glutaredoxin (Grx), Mn-dependent superoxide 
dismutase (MnSOD), thioredoxin-2 (Trx2), Trx-Reductase (TrxR), peroxiredoxin 
III (PrxIII). 
 
Figure 2. Intrinsic and extrinsic apoptotic pathways. Intrinsic, or 
mitochondrial pathways, and extrinsic, or death receptor pathway, converge to a 
common pathway involving the activation of caspase-3 by the apoptosome 
culminating in cell death execution. In type II cells, the extrinsic and intrinsic 
pathways are integrated through the cleavage of Bid by caspase-8 
consequently linking mitochondria to the control of cell death. 
 
Figure 3. Effect of mitochondrial cholesterol deposition on mitochondrial 
control of cell death. In healthy mitochondria, mGSH levels can cope with the 
ROS generated after an apoptotic stimulus. However, in cholesterol enriched 
mitochondria, the mGSH transport is concomitantly decreased resulting in 
mGSH depletion. mGSH levels below a certain threshold will compromise ROS 
detoxification leading to its accumulation resulting ultimately in cardiolipin 
oxidation and cell death. 
 
